Cassa di Compensazione e Garanzia spa Initial Margin applied to Share Section ETFPlus - 4/10/2021 New or changed instruments
The 4-Electron Cleavage of a N═N Double Bond by a Trimetallic TiNi2 Complex | Inorganic Chemistry
European Monthly ETF Market Review
Free Writing Prospectus -- ETF/ETN Guide Q2 2013
Lyxor Bund Daily (-2x) Inverse UCITS ETF Acc (EUR... ETF | FR0010869578
Kaiser Research Online - Daily Leaders - KRO Favorites Center - Mon Oct 3, 2022
Foods | Free Full-Text | The Effect of Trans Fatty Acids on Human Health: Regulation and Consumption Patterns | HTML
Mechanism of Potassium tert-Butoxide-Catalyzed Ketones Hydrogenation in the Solution Phase | The Journal of Physical Chemistry A
Lyxor Bund Daily (-2x) Inverse UCITS ETF Acc ETF | FR0010869578
A collection of bacterial isolates from the pig intestine reveals functional and taxonomic diversity | Nature Communications
Lyxor International Asset Management Share Price BTP Daily (-2x) Inverse UCITS ETF Acc
Lyxor Bund Daily (-2x) Inverse UCITS ETF - Acc | DSB FP
Lyxor 10Y US Treasury Daily (-2x) Inverse UCITS E... ETF | FR0011607084
Lyxor International Asset Management Share Price (DSUS) Lyxor UCITS ETF Daily Double Short 10y US Treasury | DSUS
Lyxor BTP Daily (-2x) Inverse UCITS ETF Acc ETF | FR0011023621
ETF Directory Europe
fp0003952_ncsr.htm
Lyxor UCITS ETF Daily Double Short Bund
Valorisation of Waste Tyre via Pyrolysis: Advances and Perspectives | Energy & Fuels
BUND2S Quote - Lyxor Bund Daily -2x Inverse UCITS ETF Fund - Bloomberg Markets
Full article: PAINWeek Abstract Book 2016
Short & Leveraged ETFs/ETPs Global Report
SGI Retail LLC D/B/A Authentic Wildomar
Lyxor 10Y US Treasury Daily (-2x) Inverse UCITS E... ETF | FR0011607084
PplD is a de-N-acetylase of the cell wall linkage unit of streptococcal rhamnopolysaccharides | Nature Communications
2020 Evidence-based Instruments Report | SGI Sustainable Governance Indicators
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study - The Lancet Oncology
